Drug Database
BA

baclofen (Xylka / Baclocur / baclofen, Ethypharm)

✓ Approved

Ethypharm Corp. · GABBR1 · 小分子

什么是 baclofen?

baclofen 是一种小分子,由Ethypharm Corp.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Xylka, Baclocur, baclofen, Ethypharm
公司Ethypharm Corp.
药物类别小分子
分子靶点GABBR1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

baclofen 作用于 1 个分子靶点:

GABBR1gamma-aminobutyric acid type B receptor subunit 1 (GABABR1, GB1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

baclofen 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersAlcoholism✓ Approved

相关研究文献

PubMedBrain communications2026-11-15

Pharmacological treatments in disorders of consciousness.

Saleh Christian C, Seyfzadeh Fatemeh F, Szymkowicz Emilie E, Alnagger Naji N et al.

Disorders of consciousness (DoC) are among the most severe and devastating neurological conditions. The poorly understood underlying pathophysiology of DoC renders the search for adequate treatment options particularly difficult. The aim of this narrative review is to provide an overview of currently available pharmacological treatments, report the limitations of current research and discuss future directions, notably potential new treatments, advances in modelling approaches, potential mechanisms of action and the development of a standardized registry. We review pharmacological treatments that promote the recovery of consciousness in patients with DoC acting on dopaminergic (amantadine, levodopa, apomorphine, methylphenidate, bromocriptine, modafinil and selegiline) and GABAergic (zolpidem, baclofen and midazolam) pathways, as well as other pharmacological treatments (tricyclic antidepressants, anticonvulsants and simvastatin) and the combination of different treatments. The literature includes a limited number of randomized controlled trials (RCTs) alongside a large body of retrospective studies and case reports, which are classified as class IV evidence. Reported improvements in arousal or responsiveness are inconsistent, reflecting marked heterogeneity in patient populations, dosing regimens and outcome measures. Risk-of-bias assessment indicated that 12 of 22 RCTs (∼55%) exhibit some concerns or a high risk of bias. Multiple correspondence analysis yielded a descriptive mapping of RCT characteristics, demonstrating how pharmacological trials in DoC are grouped. Although mechanistic hypotheses converge on dopaminergic, GABAergic and thalamocortical modulation, the current literature on pharmacological treatments in DoC remains poorly reproducible. Given the significant methodological variability (e.g. study design, patient characteristics and outcome measures) across studies, current evidence does not allow firm conclusions regarding the most effective consciousness-enhancing pharmacological treatments in DoC. To make informed decisions in terms of pharmacological treatments and move towards personalized care for patients with DoC, rigorously designed multicentre controlled trials with harmonized outcome measures conducted with mechanistic and computational approaches are required. This can be achieved through an international registry to standardize data collection and improve reproducibility and replicability.

PMID 43032840
阅读全文 →
PubMedClinical practice and cases in emergency medicine2026-11-11

Acute Dystonia Following Ifosfamide Infusion in a Young Woman with Breast Angiosarcoma: A Case Report.

Miller William S WS, Niblett Alyssa B AB, Khoury Charles A CA

Ifosfamide is an alkylating chemotherapeutic agent commonly used in the treatment of sarcomas and other malignancies. Neurotoxicity is a recognized adverse effect, most often presenting as encephalopathy. Acute movement disorders such as dystonia are rare and may be underrecognized in the emergency department. We report a 22-year-old woman receiving combination chemotherapy with doxorubicin, ifosfamide, and mesna for breast angiosarcoma who developed acute right-sided neck spasms and involuntary movements within five minutes of initiating ifosfamide infusion. Vital signs were as follows: temperature, 98.0 degrees Fahrenheit; heart rate, 97 beats per minute; respiratory rate, 18 breaths per minute; blood pressure, 130/88 millimeters of mercury; and oxygen saturation, 99% on room air. Examination revealed sustained contraction of the right sternocleidomastoid and trapezius muscles with involuntary head deviation. She had no exposure to medications commonly associated with dystonia. She was treated with intravenous thiamine, benzodiazepines, intravenous fluids, and baclofen, with subsequent improvement. Acute dystonia represents a rare manifestation of ifosfamide-induced neurotoxicity. Emergency clinicians should consider chemotherapy-related neurotoxicity in patients presenting with acute movement disorders, as early recognition and supportive management may prevent progression.

PMID 43014371
阅读全文 →
PubMedbioRxiv : the preprint server for biology2026-11-08

MR-Guided Focused Ultrasound Neuromodulation of Nucleus Accumbens to Attenuate Oral Fentanyl Motivation in A Self-Administration Rat Model.

Martin David A DA, Eldirdiri Abubakr A, Ernst Thomas T, Cunningham Eric E et al.

Transcranial low-intensity focused ultrasound (LIFU) is being explored as a non-invasive approach for neuromodulation to treat opioid use disorder (OUD). We evaluated MR-guided focused ultrasound, with LIFU, targeting nucleus accumbens (MRgLIFU-NAc) bilaterally, using MR-acoustic radiation force-imaging (MR-ARFI) to ensure accurate targeting and adjust for FUS intensity delivered at the target. Male and female rats were trained to self-administer fentanyl/sucrose (70ug/ml fentanyl citrate in 5% sucrose) or 5% sucrose alone. Three cohorts of rats (total n=76) were evaluated on progressive ratio (PR) responding for oral fentanyl/sucrose at either 4 or 24 hours post-MRgLIFU-NAc. Animals in the first two cohorts received repeated rounds of LIFU or sham (anesthesia-duration matched). In cohort 3, we used a counterbalanced within-subjects design in which rats received both LIFU and sham one week apart. Reducing sucrose concentrations decreased responding for sucrose alone more than for fentanyl/sucrose, demonstrating a role for fentanyl in the reinforcing properties of fentanyl/sucrose. Across three sonication schemes, MRgLIFU-NAc did not attenuate PR performance for oral fentanyl/sucrose at 4 or 24-hours post-LIFU relative to controls. Adjusting LIFU intensity with MR-ARFI did not correlate with changes in PR from baseline. We confirmed that NAc is the correct target by bilateral inactivation of NAc with muscimol/baclofen mixture (50 + 50 ng/side), which reduced PR responding for fentanyl/sucrose. The three sets of LIFU parameters, with repeated MRgLIFU-NAc sessions, did not produce detectable changes in oral fentanyl/sucrose motivation. Further studies are required to determine effective LIFU parameters needed to reduce NAc-dependent fentanyl motivation.

PMID 42995866
阅读全文 →
PubMedAmerican journal of obstetrics and gynecology2026-11-05

Baclofen Vaginal Suppositories in Chronic Pelvic Pain: a Randomized, Double-Blind, Placebo Controlled Trial.

Rothenberger Rodger W RW, Abraham Alyce A, Gaskins Jeremy T JT, Carbone Laurel L et al.

Pelvic floor muscle dysfunction is a common contributor to chronic pelvic pain (CPP), yet targeted treatment options remain limited. To determine whether baclofen vaginal suppositories in CPP is safe and effective when compared with placebo. This randomized, double-blind, placebo-controlled trial compared 20mg baclofen vaginal suppositories to placebo suppositories nightly in women with CPP. Women older than18 years without allergy to baclofen or the suppository base were included if they had ≥40/100 mm pain on a visual analogue scale (VAS) with palpation of the obturator internus or levator ani on standardized pelvic exam. Improvement in this standardized pelvic exam 100mm VAS pain score represented the primary outcome. Participants completed Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference, PROMIS global health, PROMIS sexual function at baseline, 4, and 8 weeks, with repeat pelvic examination at 8 weeks. The study was powered to detect the minimum clinically important difference (MCID) of 20mm on a 100mm VAS pain scale on a standardized pelvic floor muscle examination with a total sample size of 34, 17 in each group. Adverse events, pill count, and other treatments for CPP during the study period were collected. Differences between treatment groups were assessed using the Mann-Whitney test, and multiple imputation was used to account for missing data. A total of 39 women were enrolled in the study with 37 randomized.19 patients received baclofen vaginal suppositories and 18 received placebo suppositories. Demographic data was similar between groups, with similar mean age (42.5 ± 12.5 baclofen vs 46.3 ± 12.2 placebo) and body mass index (29.4 ± 6.7 vs 29.8 ± 7.6). There was a statistically and clinically significant improvement in the primary outcome of change in the 100mm VAS pain score on pelvic floor muscle examination at 8 weeks relative to baseline in the baclofen group as compared to placebo (median improvement of 33.5 mm [IQR: 30 to 46.230.0] baclofen vs 7.2 mm [0.0 to 10.0] placebo, p=<0.001). Further, patient-reported overall 100mm VAS pain was also significantly improved with baclofen when compared to placebo (median improvement 32.0 mm [14.0 to 43.0] baclofen vs 0.0 mm [-6.5 to 11.8] placebo, p=0.001) (Figure 2). Other validated questionnaires demonstrated no significant differences between baclofen and placebo. Medication compliance, assessed using Spearman correlation between the number of missed doses and the survey score at 8 weeks, did not impact the outcomes among those in the baclofen arm. There were no adverse events in the baclofen group. In the placebo group one participant had intermittent headaches and one participant had irritated vaginal skin. In this appropriately powered, randomized trial, patients experienced statistically and clinically significantly less pain with 8 weeks of nightly baclofen vaginal suppositories when compared to placebo. Baclofen suppositories were shown to be well tolerated with no adverse events.

PMID 42988098
阅读全文 →
PubMedInfection2026-11-03

Contemporary management of severe generalized tetanus: an evidence-based review.

Pothumarthy Venkata Swathi Kiran VSK, Tirlangi Praveen Kumar PK, Nagesh Savan Kumar SK, Bhat Rachana R et al.

Severe generalized tetanus remains associated with substantial mortality despite being vaccine preventable. Management is complicated by limited high-quality evidence, conflicting trial results, and the need to balance effective control of spasms and autonomic dysfunction against the risks of prolonged mechanical ventilation. We describe the management of a 57-year-old man with Ablett grade III generalized tetanus and use this case as a clinical framework for an expert narrative review. The review synthesizes randomized controlled trials, systematic reviews, meta-analyses, prospective studies, and relevant observational literature addressing neuromodulatory therapy, airway management, autonomic dysfunction, intrathecal antitoxin, and supportive critical care. The patient was managed using a multimodal strategy comprising continuous midazolam infusion, magnesium sulphate, oral baclofen, dexmedetomidine, intramuscular and intrathecal human tetanus immunoglobulin, and meticulous low-stimulation supportive care. Therapy was titrated using serial bedside assessment of neuromuscular burden. He recovered without endotracheal intubation, neuromuscular blockade, or tracheostomy and was discharged on day 21. We argue that discordant findings in tetanus trials are substantially attributable to heterogeneity in disease severity, clinical practice, airway management thresholds, and resource availability, rather than to true therapeutic inconsistency. Available evidence supports a physiology-directed multimodal approach using agents with complementary mechanisms to suppress spasms and autonomic dysfunction while preserving spontaneous ventilation whenever safely feasible. Management of severe tetanus should focus on achieving physiological targets rather than escalating individual drugs. A structured, individualized, multimodal neuromodulatory strategy delivered within an experienced, low-stimulation critical care environment may allow selected patients to be managed without mechanical ventilation; safety cannot be established from a single case and requires prospective evaluation. Greater emphasis should also be placed on preventive adult immunization, as vaccination remains the intervention most likely to reduce the burden of severe tetanus.

PMID 42975860
阅读全文 →
PubMedSeminars in perinatology2026-11-01

Motor manifestations of kernicterus spectrum disorder: Diagnosis and treatment.

Can Afra A, Gelineau-Morel Rose R

Kernicterus Spectrum Disorder (KSD) is a chronic neurologic condition resulting from bilirubin neurotoxicity and remains a leading global cause of dyskinetic cerebral palsy (CP). Injury to the globus pallidus and related neural networks leads to characteristic movement disorders, most commonly dystonia and choreoathetosis, which often emerge months after the episode of hyperbilirubinemia. This delay contributes to underrecognition and missed opportunities for early intervention. In this review, we summarize motor manifestations of KSD and evaluate current approaches to early diagnosis and treatment. Available predictive and diagnostic tools include the modified Bilirubin-Induced Neurologic Dysfunction (BIND) score, brain magnetic resonance imaging, dystonia rating scales, and the KSD diagnostic toolkit. Although evidence for treatment of movement disorders specific to KSD remains limited, management can be informed by the broader literature on dyskinetic CP and acquired dystonia. Current interventions include oral medications, botulinum neurotoxin injections, intrathecal baclofen, deep brain stimulation (DBS), and rehabilitation therapies. Interventions should be individualized according to motor phenotype, functional goals, and patient priorities. Future research is needed to define effective interventions, identify individuals most likely to benefit from specific therapies, and develop personalized treatment strategies.

PMID 42966715
阅读全文 →

注册免费账户还可查看另外 8185 篇文献

免费注册查看全部文献 →

了解更多baclofen